GSK Headquarters: London, United Kingdom Number of employees: 65,000 Year founded: 2000 Revenue (2025): $40.1 billion Forbes overall rank: 57 GSK company reported ~31.4 billion ($41.9 billion) in annual 2025 sales driven by strong growth in its specialty medicines and vaccines portfolios, including HIV therapies such as Dovato (dolutegravir/lamivudine) and Cabenuva (cabotegravir/rilpivirine), the blockbuster RSV vaccine Arexvy (respiratory syncytial virus vaccine, adjuvanted) and expanding oncology products like Jemperli (dostarlimab-gxly)
Made-to-order sequences beyond the standard catalog
The IV drip for skin brightening is formulated to combat these signs of aging by promoting collagen production and improving skin elasticity
In the context of prostate cancer development, Epithalon has shown the ability to activate apoptosis in cancer cells and inhibit malignant transformation, providing a potential therapeutic effect in cancer treatment
Shaking creates foam, introduces air, and subjects the peptide to mechanical stress
BPC-157 + CJC-1295 + Ipamorelin: Longevity and Body Composition For patients focused on body composition, longevity, and performance optimisation, adding CJC-1295 and Ipamorelin to a BPC-157 protocol creates a powerful synergy
